Sonnet biotherapeutics announces interim data in two phase 1 dose-escalation trials of son-1010

The sb101 and sb102 studies have together dosed 36 subjects to date as dose escalation continues cytokine data show extended pharmacokinetics of son-1010 with controlled induction of ifnΓ and no signs of cytokine release syndrome all but one patient remain on study, with evidence of tumor improvement at 6 months in one patient princeton, nj / accesswire / november 2, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of son-1010 dosing in several cohorts has been formally reviewed in both phase 1 clinical trials and that dose escalation is continuing as early data becomes available. son-1010 is a proprietary version of human interleukin-12 (il-12), configured using sonnet's fully human albumin binding (fhab®) platform.
SONN Ratings Summary
SONN Quant Ranking